Gilead, Idenix deal

The U.S. Patent and Trademark Office declared a patent interference between a patent application from Idenix and U.S. Patent No. 7,429,572 owned by Gilead. Both patents cover the use of nucleoside compounds to treat HCV infection. The PTO is seeking to determine which company is entitled to patent protection, as both claim rights to the same nucleoside formula. The PTO said Gilead has the burden of proof to show that it invented the technology before Idenix. Each party must submit proposed motions for consideration, as well as any relief requested, by March 28. ...